Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2006-12-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inhaled milrinone 5 mg
Inhaled milrinone 5 mg(as for the injectable solution)
Inhaled milrinone 5 mg
Inhaled milrinone 5 mg (as for the injectable solution)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inhaled milrinone 5 mg
Inhaled milrinone 5 mg (as for the injectable solution)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High risk patients: NYHA class II-III
* Preoperative diagnostic of pulmonary hypertension:
* Systolic pulmonary artery pressure (sPAP) \> 35 mm Hg; or
* Mean pulmonary artery pressure (mPAP) \> 25 mm Hg; or
* mAP/mPAP \< 3.0 (after induction of anesthesia).
Exclusion Criteria
* Contraindication to transesophageal echocardiography (TEE)
* Hemodynamic instability before surgery
* Emergency surgery
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Fonds de la Recherche en Santé du Québec
OTHER_GOV
St. Justine's Hospital
OTHER
Montreal Heart Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andre Denault
MD PhD FRCPC ABIM-CCM
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrée Denault, MD PhD FRCPC
Role: PRINCIPAL_INVESTIGATOR
Montreal Heart Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Montreal Heart Institute
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICM 06-888
Identifier Type: -
Identifier Source: org_study_id